Notice from the Executive Officer Submission Requirements: Flash Glucose Monitoring (FGM)

To help manufacturers prepare a submission to have Flash Glucose Monitoring products (FGM) considered for funding through the Ontario Drug Benefit Program, the Ministry of Health has

updated its Ontario Guidelines for Drug Submission and Evaluation (Guidelines) by adding a new section - **Part XII.2. - Guidelines for Flash Glucose Monitoring Products.**

The updated Guidelines take effect on July 24, 2019.

The updated Guidelines reflect current policy requirements for manufacturer submissions regarding FGM products.

Highlights include:

- Effective July 24, 2019, the ministry will accept FGM product submissions and consider funding through the ODB program. If an FGM product is listed on the Formulary, the FGM product would be eligible for reimbursement when it is prescribed for ODB-eligible recipients.

- New section (Part XII.2.) to describe submission requirements and policies that relate to FGMs.

The updated Guidelines will also be available on the ministry's website by July 24, 2019.

Ontario